Frequency of non-CAEs in ponatinib-treated patients
| Non-CAEs . | Cumulative incidence, n (%) (n = 78) . | Ponatinib 45 mg/d, n (%) . | Ponatinib 30 mg/d, n (%) . | Ponatinib 15 mg/d, n (%) . |
|---|---|---|---|---|
| Thrombocytopenia | 31 (39.7) | 18 (23.1) | 10 (12.8) | 3 (3.8) |
| Abdominal pain | 26 (33.3) | 16 (20.5) | 7 (9.0) | 3 (3.8) |
| Anemia | 22 (28.2) | 16 (20.5) | 4 (5.1) | 2 (2.6) |
| Elevated lipase | 22 (28.2) | 11 (14.1) | 9 (11.5) | 2 (2.6) |
| Rash | 21 (26.9) | 13 (16.7) | 6 (7.7) | 2 (2.6) |
| Neutropenia | 16 (20.5) | 12 (15.4) | 2 (2.6) | 2 (2.6) |
| Pancreatitis | 8 (10.3) | 5 (6.4) | 3 (3.8) | 0 (0.0) |
| Diabetes Mellitus | 2 (2.6) | 1 (1.3) | 1 (1.3) | 0 (0.0) |
| Non-CAEs . | Cumulative incidence, n (%) (n = 78) . | Ponatinib 45 mg/d, n (%) . | Ponatinib 30 mg/d, n (%) . | Ponatinib 15 mg/d, n (%) . |
|---|---|---|---|---|
| Thrombocytopenia | 31 (39.7) | 18 (23.1) | 10 (12.8) | 3 (3.8) |
| Abdominal pain | 26 (33.3) | 16 (20.5) | 7 (9.0) | 3 (3.8) |
| Anemia | 22 (28.2) | 16 (20.5) | 4 (5.1) | 2 (2.6) |
| Elevated lipase | 22 (28.2) | 11 (14.1) | 9 (11.5) | 2 (2.6) |
| Rash | 21 (26.9) | 13 (16.7) | 6 (7.7) | 2 (2.6) |
| Neutropenia | 16 (20.5) | 12 (15.4) | 2 (2.6) | 2 (2.6) |
| Pancreatitis | 8 (10.3) | 5 (6.4) | 3 (3.8) | 0 (0.0) |
| Diabetes Mellitus | 2 (2.6) | 1 (1.3) | 1 (1.3) | 0 (0.0) |